| Study‐ID | Setting | Condition | Indication | Scale | Drug | Daily dose | Duration, weeks | Number randomised |
| Finkel 1995 | Nursing homes | AD, VDa | Agitation | CMAI | Thiothixene | 0.25 mg to 18 mg | 11 | 33 |
| Auchus 1997 | Community‐dwelling | AD | Agitation | CMAI‐SF | Haloperidol | 3 mg | 6 | 12 |
| Teri 2000 | Community‐dwelling | AD | Agitation | CMAI | Haloperidol | 0.5 mg to 3 mg | 16 | 70 |
| Allain 2000 | Nursing home or hospitalised | AD, VD, mixed type | Agitation | MOSESb | Haloperidol | Up to 6 mg | 3 | 306 |
| Tariot 2006 | Nursing homes | AD | Psychosis | NPI‐NH psychosisc | Haloperidol | 0.5mg to 12 mg | 10 | 284 |
| Devanand 1998 | Community‐dwelling | AD | Psychosis Agitation |
BPRS psychosisc BSSD psychomotor agitation item |
Haloperidol | 0.5 mg to 0.75 mg or 2 mg to 3 mg | 6 | 66 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.